Gilead's bi-annual HIV prevention jab gets FDA approval: How much does it cost and how it works? All you need to know…
American biopharmaceutical major Gilead Sciences, has recieved approval from the United States' Food and Drug Administration (US FDA), for its bi-annual HIV prevention injection, to be marketed as 'Yeztugo'.
Gilead shares briefly jumped 3.5 per cent — its biggest gain nearly a month, and rose 17 per cent year-on-year (YoY), till market close on June 18, Bloomberg reported. The stock outperforming a 2 per cent increase in the S&P 500 index.
Lenacapavir, marketed under the brand name Yeztugo, has been shown to reduce the risk of HIV transmission by more than 99.9 percent in adults and adolescents — making it functionally akin to a powerful vaccine, according to an AFP report.
Hailed by activists as the world's 'best tool' to fight the HIV virus, especially since no vaccine is yet available, the medicine has to be administered only twice a year and are compatible for a wide range of people, as per the report.
'This is a milestone moment in the decades-long fight against HIV. We now have a way to end the HIV epidemic,' Gilead CEO Daniel O'Day said in an emailed statement to Bloomberg.
The injection demonstrated 'powerful ability' to ward off HIV infection in two major international studies last year, the BB report added. AFP reported that results from both trials were published in The New England Journal of Medicine, and the journal Science named lenacapavir its 2024 'Breakthrough of the Year'.
As many as 1.3 million people are infected with the HIV virus each year, with the highest rate in Africa. Daily pills do work, but can be forgotten by patients or also lead to stigma as the bottle can reveal people's health status.
One international study published in November 2024 showed that the drug prevented all but two HIV cases among 2,180 men and transgender people — a rate 96 per cent lower than the background incidence level in that population.
And in June 2025, Gilead said a trial of the shot in 2,000 women and adolescent girls in sub-Saharan Africa prevented an 'unprecedented' 100 per cent of HIV cases.
It also outperformed the company's old HIV prevention daily oral pill Truvada in both studies.
Yes, there are some side effects. Around 1.2 per cent of the people in the study had reactions at the injection site and stopped taking the medicine, the Bloomberg report said.
Other reported side effects include headache, and nausea, according to the AFP report.
Gilead said it will price Yeztugo at $28,218 per year (around ₹ 24.50 lakh), compared to the $26,400 list price of its daily HIV prevention pill, Descovy. There was no specific price given for India or other global markets.
Lenacapavir's current list price for its previously approved use as a treatment for HIV is $39,000 annually, the AFP report noted.
'We are working to make Yeztugo accessible for anyone who needs or wants it and expect to see broad insurance coverage,' Gilead spokeswoman Blair Baumwell told AFP via email.
The jab will compete with GSK-arm ViiV Healthcare's Apretude prevention shot, which is administered alternate months. This jab costs ₹ 15,200 for a 600mg/3ml vial, according to data on IndiaMart.
Notably, Gilead already sells the same drug, lenacapavir, as a treatment for people with multidrug-resistant HIV under the brand Sunlenca — priced at ₹ 23000/box for 300 mg tablets in India, according to IndiaMart.
The California-based company is looking at making the drug a 'best-seller' in rich countries, but will also be pushed toward faster roll-out in poorer and middle-income countries that face HIV crisis. And analysts surveyed by Bloomberg expect Yeztugo sales to surpass $4 billion per year by 2031.
The report added that Gilead has already filed for approval in a number of countries, including Australia, Brazil, Canada, the European Union, South Africa, and the EU Medicines For All program, which helps speed the review of drugs that will be used in developing countries.
In October, Gilead signed agreements with six pharma companies to produce and distribute generic versions of the drug in around 120 low-income and middle-income countries, pending regulatory approval, AFP reported.
In a separate deal in December, Gilead announced partnership with the United Nations' Global Fund, the US President's Emergency Plan for AIDS Relief (PEPFAR), and others, to purchase doses for two million people. However, Donald Trump's cuts to the PEPFAR program could now impact this development.
(With inputs from Bloomberg, AFP)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Tripura CM mulls sex education in Class VIII-XII curriculum
Agartala: Tripura CM on Friday said the state govt is considering the introduction of sex education in the curriculum for students in Classes VIII to XII. Speaking at the legislative forum in the state assembly, Saha emphasised the importance of this initiative, stating, "We are considering incorporating sex education and HIV/AIDS awareness in the school curriculum in Class VIII-XII. Tired of too many ads? go ad free now This is not a matter of controversy, it is a necessity." He also encouraged community involvement, suggesting that MLAs could allocate funds to support HIV/AIDS patients. Saha highlighted the equal impact of HIV/AIDS on both boys and girls and stressed the importance of engaging youth in sports, cultural activities, and other creative pursuits to steer them away from drug addiction and reduce their vulnerability to HIV/AIDS. He said Tripura was the first state in India to introduce Red Ribbon Clubs in schools and plans to create youth ambassadors to lead campaigns against drug abuse. Expressing concern over the rising number of HIV/AIDS cases and injecting drug users, particularly among teenagers, Saha said an average of 120 new HIV infections are reported each month in the state, despite preventive efforts by the state AIDS Control Society. In response to a proposal by Congress legislator Sudip Roybarman, the chief minister supported the idea of adding a dedicated chapter on sex education and HIV/AIDS to the school curriculum to raise awareness among the most vulnerable age group. Additionally, he suggested that each MLA could allocate Rs 1 lakh per year from their area development fund for initiatives against drugs and HIV.
New Indian Express
3 hours ago
- New Indian Express
More microplastics in glass bottles than in plastic bottles: Study
PARIS: Drinks including water, soda, beer and wine sold in glass bottles contain more microplastics than those in plastic bottles, according to a surprising study released by France's food safety agency Friday. Researchers have detected the tiny, mostly invisible pieces of plastic throughout the world, from in the air we breathe to the food we eat, as well as riddled throughout human bodies. There is still no direct evidence that this preponderance of plastic is harmful to human health, but a burgeoning field of research is aiming to measure its spread. Guillaume Duflos, research director at French food safety agency ANSES, told AFP the team sought to "investigate the quantity of microplastics in different types of drinks sold in France and examine the impact different containers can have". The researchers found an average of around 100 microplastic particles per litre in glass bottles of soft drinks, lemonade, iced tea and beer. That was five to 50 times higher than the rate detected in plastic bottles or metal cans. "We expected the opposite result," PhD student Iseline Chaib, who conducted the research, told AFP. "We then noticed that in the glass, the particles emerging from the samples were the same shape, colour and polymer composition -- so therefore the same plastic -- as the paint on the outside of the caps that seal the glass bottles," she said. The paint on the caps also had "tiny scratches, invisible to the naked eye, probably due to friction between the caps when there were stored," the agency said in a statement. This could then "release particles onto the surface of the caps", it added.
Indian Express
4 hours ago
- Indian Express
As US FDA approves HIV prevention drug Lenacapavir, expert says ‘India needs to take lead for its equitable, timely distribution
The United States Food and Drug Administration (FDA) on Wednesday approved Lenacapavir (LEN), the most promising HIV prevention medicine to be made so far, and according to Dr I S Gilada, president emeritus, AIDS Society of India, the real breakthrough would be when LEN becomes accessible, affordable and available to everyone in India and across the world. Lenacapavir is an antiretroviral medicine that is used for HIV prevention as a pre-exposure prophylaxis or PrEP. PrEP is a medication that can reduce the risk of HIV infection for individuals who are HIV-negative but are at risk of contracting the virus. The results of two key studies have shown that it helps prevent 99.9 per cent of all HIV transmission. 'LEN is an injectable PrEP that is to be taken twice yearly,' said Dr Glory Alexander, president of AIDS Society of India (ASI) and founder director of ASHA Foundation, Bengaluru. PrEP was first approved by the US FDA in 2012, but the Indian government's National AIDS Control Organisation is yet to roll it out. 'If we invest in HIV prevention, we not only protect people's health but also save expenses in providing lifelong HIV care, including lifelong antiretroviral therapy (ART). HIV prevention must remain at the centre-stage of our national AIDS response,' said Dr Gilada. 'Indian regulators should work with Indian generic manufacturing companies to ensure that 'made in India' generic LEN versions when available, are first rolled out in India,' Dr Gilada told The Indian Express. 'The scientific breakthrough translates into public health impact in terms of stopping the spread of HIV infection. The major impediment is the cost: LEN as PrEP to be sold as Yeztugo by Gilead is priced at US$ 28,218 per person per year. However, Gilead's wisdom by giving voluntary licenses to four Indian generic companies, gives hope that the medicine may cost less than US$ 100 – that is 0.3 per cent of the innovator's cost,' Dr Gilada explained. 'India needs to lead from the front for LEN's equitable and timely distribution at the required scale to prevent HIV transmission and help end AIDS,' said Dr Gilada, adding that only India can deliver LEN to all those in need worldwide, in terms of quality, quantity and speed. Though India meets 92 per cent of the global requirement for ART and the global community (WHO, UNAIDS, Global Fund, World Bank, etc) widely uses Indian generic pharma for their strategies like Treatment as Prevention (TasP), Test and Treat, Post-exposure Prophylaxis (PEP), PreP, etc, it is unfortunate that they are shy to acknowledge this, he said. Gilead had faced a lot of backlash from health advocates and communities last year over the astronomical pricing for LEN, pegged at over US$ 40,000 per person per year, which has now been slashed by 30 per cent. Earlier, Gilead's Hepatitis C treatment, which cost $84,000 in the US for a three-month course, was made available in India for less than $300. So the firm knew what was to be done this time, and granted voluntary licensing to six generic manufacturers, including four Indian: Dr Reddy's Laboratories, Emcure, Hetero Healthcare, and Viatris. 'All international antiretroviral therapy and prevention guidelines are conceptualised and implemented on the strength of India. Only India can meet the global demand for LEN at such low cost, just as it did for ART, at 0.3 per cent of the innovator's cost,' Dr Gilada said. Anuradha Mascarenhas is a journalist with The Indian Express and is based in Pune. A senior editor, Anuradha writes on health, research developments in the field of science and environment and takes keen interest in covering women's issues. With a career spanning over 25 years, Anuradha has also led teams and often coordinated the edition. ... Read More
